Meridian Medical Technologies Inc. received approval yesterday to market in Europe its new device for detecting a heart attack, and said it hopes to launch human trials with the device later this year so it can seek Food and Drug Administration approval to market it in the United States.
Columbia-based Meridian hopes its PRIME ECG device emerges as a new standard diagnostic for determining if a person is experiencing a heart attack, and might one day replace the electrocardiogram, which has been the standard of care for more than 50 years.
The approval marks the first significant medical device Meridian can market outside its prime business of making pre-filled automatic injectors for treating allergies and the effects of chemical warfare.
Shares in Meridian closed yesterday at $6.3125, up 87.5 cents, on trading of 142,000 shares. The company's average daily trading volume is about 20,000 shares.
James H. Miller, Meridian's president, said the company is in discussions with four major medical device companies about a potential marketing agreement for the device. He declined to name the interested parties.
Pub Date: 1/08/99